Evidence map›Paper›PMID 42619894›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Biomarker-Informed Interpretation of Dyadic Cognitive Function Index Scores in Cognitively Unimpaired Older Adults.

Ambre Mounié, Kenichiro Sato, Saki Nakashima, Yoshiki Niimi, Takeshi Iwatsubo

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ambre MouniéDementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Kenichiro SatoDementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Saki NakashimaDementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Yoshiki NiimiDementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
Takeshi IwatsuboDementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
NIA NIH HHS R01 AG063689NIA NIH HHS U19 AG010483NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

Introduction: Participant- and study partner-reported Cognitive Function Index scores may provide complementary information, but it remains unclear whether Alzheimer's disease biomarkers are associated with CFI scores across reporters, reporter-specific imbalance, or both. Methods: Using A4/LEARN screening data (screening sample, N = 1,686; primary dyadic analytic sample, N = 1,682; CDR global score = 0), we jointly modeled participant-reported (CFI-PT) and study partner-reported (CFI-SP) scores in long format to evaluate biomarker associations with CFI scores and biomarker × reporter interactions. As a secondary analysis, we compared tau PET with plasma p-tau217. Results: In an A4/LEARN-adapted regional extent model, reporter balance varied across amyloid regional extent categories, with the largest participant-leading contrast observed in the exploratory restricted early cortical subgroup. Tau PET was associated with higher CFI scores, but this association did not differ detectably between reporters. Plasma p-tau217 showed no clear CFI association or reporter-specific interaction in the A4-derived, amyloid-enriched subset. Discussion: Amyloid regional extent and tau PET were associated with different features of dyadic CFI data: reporter balance and CFI burden across reporters, respectively. Joint interpretation of CFI-PT and CFI-SP may support biomarker-informed interpretation of the instrument, although the cross-sectional findings require replication and longitudinal validation.

Indexed as

Alzheimer’s diseaseamyloid PETCognitive Function Indexplasma p-tau217tau PET

Identifiers

PMID42619894
PMCPMC13484350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.